Biogen Stock Forecast, Price & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BIIB stock has decreased by 8.4% and is now trading at $269.56.
View which stocks have been most impacted by COVID-19.

33 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 5 sell ratings, 15 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Biogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
View analyst ratings for Biogen or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Biogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Biogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, February 3rd 2021.
View our earnings forecast for Biogen.

Biogen will be holding an earnings conference call on Wednesday, February 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Biogen Inc. (NASDAQ:BIIB) announced its quarterly earnings data on Wednesday, October, 21st. The biotechnology company reported $8.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.06 by $0.78. The biotechnology company had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.34 billion. Biogen had a return on equity of 51.00% and a net margin of 35.63%. The firm's quarterly revenue was down 6.2% compared to the same quarter last year. During the same quarter last year, the company posted $9.17 EPS.
View Biogen's earnings history.

Biogen declared that its board has initiated a share repurchase program on Monday, December 23rd 2019, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its shares are undervalued.

33 brokers have issued 12 month price objectives for Biogen's shares. Their forecasts range from $175.00 to $450.00. On average, they anticipate Biogen's stock price to reach $305.97 in the next twelve months. This suggests a possible upside of 13.5% from the stock's current price.
View analysts' price targets for Biogen or view Wall Street analyst' top-rated stocks.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Novavax (NVAX) and United Therapeutics (UTHR).
View all of BIIB's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include DNB Asset Management AS (0.11%), Gateway Investment Advisers LLC (0.04%), State of Alaska Department of Revenue (0.04%), Hexavest Inc. (0.03%), Rhenman & Partners Asset Management AB (0.03%) and Exchange Traded Concepts LLC (0.02%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, State of Alaska Department of Revenue, Hexavest Inc., Busey Wealth Management, Cullinan Associates Inc., Exchange Traded Concepts LLC, Sowell Financial Services LLC, and Gateway Investment Advisers LLC. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, and Stephen A Sherwin.
View insider buying and selling activity for Biogen or view top insider-selling stocks.

BIIB stock was acquired by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Rhenman & Partners Asset Management AB, FNY Investment Advisers LLC, Prairiewood Capital LLC, Traynor Capital Management Inc., OneAscent Financial Services LLC, NuWave Investment Management LLC, and IFM Investors Pty Ltd. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen or or view top insider-buying stocks.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $269.56.

Biogen has a market capitalization of $41.48 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]